OncoMatch/Multiple Myeloma (MM)/TP53 / 17p deletion
Multiple Myeloma (MM)TP53 / 17p deletion Clinical Trials
TP53 mutation and/or 17p13.1 deletion (del17p) occur in approximately 10% of newly diagnosed myeloma and up to 30–40% of relapsed/refractory cases, defining a high-risk feature per IMWG and ISS criteria. Del17p/TP53-altered myeloma has poor outcomes with standard therapy and represents an unmet need. Trials investigate novel combinations including anti-CD38 quadruplets, p53-pathway targeting agents, and CAR-T/bispecific antibody strategies specifically in high-risk cytogenetic myeloma.
Top recruiting TP53 / 17p deletion Multiple Myeloma (MM) trials
Ranked by phase and US site count. See all 13 trials matched to your profile →
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Merck Sharp & Dohme LLC
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Emory University
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center